Side-by-side · Research reference

MOTS-cvsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/68 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly doseLee 2015

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

MOTS-c

Testagen

Primary target

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

Testicular tissue; proposed nuclear DNA interaction

Pathway

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

Unknown — no HPG axis data

Origin

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

MOTS-c

Testagen

Standard dose

5–10 mg / weekLee 2015

Experimental, extrapolated from animal data. No human RCT-derived dose.

—

Frequency

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

Once daily or alternate days

Lower / starter dose

2.5–5 mg / week

Recommended due to limited human data.

—

Evidence basis

Animal + anecdotalLee 2015 Reynolds 2021 A first-in-human phase 1 study 2021

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Animal mechanistic / in vitro onlyFedoreyeva 2011

Duration

4–12 weeks (experimental)

Optimal cycle length unknown.

—

Reconstitution

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

Sterile water or bacteriostatic saline

Timing

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

—

Half-life

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

Unknown — likely minutes (short peptide)

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

03Metabolic / Fat Loss Evidence

Parameter

MOTS-c

Testagen

Primary fat target

Diet-induced / metabolic obesity; systemic fat utilization

—

Quantified reduction

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

—

IGF-1 impact

No direct IGF-1 pathway; AMPK-mediated

—

Effect on lean mass

High dose significantly ↑ lean mass in mice

—

Insulin sensitivity

Reversed HFD insulin resistance in 7 days (mice)Lee 2015

—

Triglycerides

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

—

Glucose metabolism

Improved glucose tolerance; GLUT4 upregulationLee 2015

—

Effect reversibility

Unknown — no long-term follow-up data

—

Context dependency

No effect in normal-chow mice; requires metabolic stressReynolds 2021

—

Key publication

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015 Reynolds 2021 Kim 2018

—

04Side Effects & Safety

Parameter

MOTS-c

Testagen

Injection site reaction

Mild irritation (reported)

—

Fluid retention / Edema

Not reported

—

Glucose intolerance

Improves glucose toleranceLee 2015

—

Cardiovascular

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

—

Cancer risk

Contradictory data — some models suggest pro-proliferative effects

—

CNS / Neurological

Insomnia, headache (anecdotal reports)

—

GI symptoms

Nausea, stomach discomfort (reported)

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Evidence quality

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

Testagen

·Active testicular malignancy

Relative Contraindications

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

MOTS-c

Testagen

1. Reconstitution

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Injection site

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Timing

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Needle

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

06Stack Synergy

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction

Testagen

— no documented stacks